While reporting financial results for the first quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its earnings and adjusted earnings guidance for the full-year 2022, while maintaining annual revenue outlook.
from RTT - Earnings https://ift.tt/ZQsCepY
via IFTTT
No comments:
Post a Comment